Overview
Clinical Meaning
Gout pharmacologic management at the NP level requires mastery of urate lowering therapy (ULT) mechanisms and flare prophylaxis strategies.
PMHNP
PMHNP
Gout pharmacologic management at the NP level requires mastery of urate-lowering therapy (ULT) mechanisms and flare prophylaxis strategies. Hyperuricemia results from either uric acid overproduction (10%) or underexcretion (90%). Xanthine oxidase inhibitors (XOIs) — allopurinol and febuxostat — block the enzyme that converts hypoxanthine → xanthine → uric acid, reducing production. Uricosuric agents (probenecid, lesinurad) inhibit URAT1 transporters in the proximal tubule, increasing renal uric acid excretion. Pegloticase (recombinant uricase) converts uric acid to the more soluble allantoin for refractory tophaceous gout. ULT initiation mobilizes crystal deposits, paradoxically triggering flares through NLRP3 inflammasome activation; therefore, flare prophylaxis with low-dose colchicine (0.6 mg daily-BID) or low-dose NSAID is co-prescribed for 3–6 months. The treat-to-target strategy aims for serum uric acid < 6 mg/dL (< 5 mg/dL in tophaceous disease). Pharmacogenomic considerations include HLA-B*5801 screening before allopurinol (risk of DRESS/SJS in carriers), CYP2C9 considerations for febuxostat, and dose adjustment for renal impairment.
Unlock full lesson + practice questions
4 more sections with scenarios, priorities, and review drills.
Final rapid review before practice
Next study step
Finish the lesson first, then choose a focused activity to apply what you just reviewed.
Continue studying
Sign in to save progress on this lesson.
Unlock the interactive lesson quiz with a plan that includes this PMHNP pathway. You can still explore topic-filtered questions from the bank hubs below.